Immunogenicity and safety of COVID-19 booster vaccination: A population-based clinical trial to identify the best vaccination strategy-Reference-Cited by-同舟云学术

Immunogenicity and safety of COVID-19 booster vaccination: A population-based clinical trial to identify the best vaccination strategy

Published:2024-08 Issue: Volume:173 Page:105661
ISSN:1386-6532
Container-title:Journal of Clinical Virology
language:en
Short-container-title:Journal of Clinical Virology

Author:

Sieghart Daniela^ORCID,Hana Claudia A.,Dürrschmid Caroline,Heinz Leonhard X.,Haslacher Helmuth,Zlesak Markus,Piccini Giulia,Manenti Alessandro,Montomoli Emanuele,Jorda Anselm,Fedrizzi Clemens,Hasenoehrl Timothy,Zdravkovic Andrej,Anderle Karolina,Wiedermann Ursula,Drapalik Susanne,Steinbrecher Helmut,Bergmann Felix,Firbas Christa,Jordakieva Galateja,Wagner Barbara,Leonardi Margherita,Pierleoni Giulio,Ballini Matilde,Benincasa Linda,Marchi Serena,Trombetta Claudia,Perkmann Thomas,Crevenna Richard,Zeitlinger Markus,Bonelli Michael,Aletaha Daniel^ORCID,Radner Helga

Publisher

Elsevier BV

Reference25 articles.

1. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection;Khoury;Nat. Med.,2021

2. Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine;Mizrahi;Nat. Commun.,2021

3. (ECDC) ECfDPaC. Country overview report: week 26 2022 https://covid19-country-overviews.ecdc.europa.eu/vaccination.html. 2022 Last access 20.08.2022.

4. Federal Ministry Republic of Austria of Social Affairs H, Care and consumer protection. Covid-19 Impfungen: Anwendungsempfehlungen des Nationalen Impfgremiums, Version 9.0; Stand: 4.3.2022 2022 [updated 18.3.2022. Available from: https://www.sozialministerium.at/Corona-Schutzimpfung/Corona-Schutzimpfung-Fachinformationen.html. Last access 24.08.2022.

5. Quantitative measurement of anti-SARS-CoV-2 antibodies: analytical and clinical evaluation;Higgins;J. Clin. Microbiol.,2021